Discrepancies observed between the outcomes of the KEYNOTE-789 and CheckMate 722 trials and the more favorable results noted in the IMpower 150 trial indicate that supplementing immunotherapy with vascular endothelial growth factor (VEGF) targeted therapy can augment the efficacy of EGFR mutation-positive NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.